Non-Small-Cell Lung Cancer | Pharmacor | G7 | 2014

Last Updated 20 October 2014
Biomarker- and histology-driven prescribing is standard practice in the treatment of non-small-cell lung cancer (NSCLC) across the major pharmaceutical markets. The treatment of NSCLC patients including that of molecularly defined subpopulations continues to evolve, driven by the development of novel agents and increasingly, associated biomarkers and companion diagnostics. Codeveloping a drug and a companion diagnostic is one of the most promising avenues for commercial success. Several underserved areas of high unmet need offer significant commercial opportunity for innovative agents.

Login to access report

launch Related Market Assessment Reports